Workflow
上海复星医药(集团)股份有限公司 关于2025年度第二期科技创新债券发行完成的公告
Sou Hu Cai Jing·2025-08-10 16:56

Group 1 - The company has completed the issuance of the second phase of technology innovation bonds for the year 2025, with a registered amount of RMB 40 billion, valid for two years from March 20, 2025 [1][2] - The first phase of medium-term notes was issued in April 2025, totaling RMB 5 billion [1] - The company’s affiliate, Fosun United Health Insurance Co., Ltd., participated in the subscription of the second phase of debt financing tools, with a final allocation of RMB 30 million [1] Group 2 - On August 7, 2025, the company’s subsidiary, Nantong Jianjia, signed a loan agreement with Nantong Rural Commercial Bank for RMB 20 million, with a loan term from July 23, 2025, to December 21, 2028 [6] - The company provided a joint liability guarantee for the loan, with a guarantee period of three years after the loan repayment deadline [6][10] - The company has approved a total guarantee limit of RMB 35,048 million, which includes guarantees for its subsidiaries [11][30] Group 3 - As of August 8, 2025, the total amount of external guarantees provided by the group is approximately RMB 23,930 million, accounting for 50.64% of the net assets attributable to shareholders as of December 31, 2024 [30] - There are no overdue guarantee matters as of the same date [31]